Turakhia Minang 4
4 · iRhythm Holdings, Inc. · Filed Feb 27, 2026
Research Summary
AI-generated summary of this filing
iRhythm (IRTC) Chief Med/Science Officer Minang Turakhia Receives 10,034 RSUs
What Happened
- Minang Turakhia, iRhythm's Chief Medical/Scientific Officer & EVP, Advanced Technology, was granted 10,034 Restricted Stock Units (RSUs) on February 25, 2026. The Form 4 reports the acquisition at $0.00 (award/grant), meaning this was a compensation grant rather than a market purchase.
Key Details
- Transaction date and type: 2026-02-25 — Award/Grant of 10,034 RSUs (code A).
- Reported price/value: $0.00 reported on the Form 4 (award grant).
- Vesting: 25% of the RSUs vest on March 1, 2027, then 25% on each one-year anniversary thereafter, contingent on continued service (per footnote).
- What an RSU is: each RSU represents a contingent right to receive one share of common stock upon vesting.
- Shares owned after transaction: Not specified in the filing.
- Filing timeliness: Form filed 2026-02-27 (appears timely under standard Form 4 rules).
Context
- This is a standard equity compensation grant to an executive (retention/incentive), not an open-market purchase or sale. Such grants are routine and reflect compensation policy rather than direct trading sentiment; they do not indicate an immediate purchase of shares until/if the RSUs vest and are settled.
Insider Transaction Report
Form 4
Turakhia Minang
CHIEF MED/SCI OFCR EVP ADVTECH
Transactions
- Award
Common Stock
[F1]2026-02-25+10,034→ 58,933 total
Footnotes (1)
- [F1]These securities are Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs vest on March 1, 2027 and each one-year anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date.
Signature
/s/ Marc Rosenbaum, attorney-in-fact|2026-02-27